ISELIN, N.J., July 30 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that it has been awarded US Patent #7,569,643 pertaining to its bioresorbable reverse thermal gelation polymer technology. This represents the latest in a series of patents covering this novel technology and pertains to the application of these materials in the reduction of post-operative adhesion formation. Dr. Eli Pines, the Company's Vice President and Chief Scientific Officer stated, "The novelty of these materials is that they can be delivered to difficult to access sites in the body as a liquid through a syringe or as a spray and, once exposed to body temperature, rapidly transition to a resorbable, adherent, high viscosity gel. Thus, they are ideally suited as anti-adhesion materials in spine and tendon surgery."
About SyntheMed, Inc.
SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the commercialization of REPEL-CV(TM) Bioresorbable Adhesion Barrier and the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technologies.
Statements in this Press Release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain FDA and other required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008 for a description of these, as well as other, risks and uncertainties.
|SOURCE SyntheMed, Inc.|
Copyright©2009 PR Newswire.
All rights reserved